Tag Archives: TEV’574

Sanofi and Teva Collaborate on Inflammatory Bowel Disease Treatment, TEV’574, in $1.5 Billion Deal

Posted on 5, October 2023 by

(IN BRIEF) Sanofi and Teva Pharmaceuticals have announced a collaboration to co-develop and co-commercialize TEV’574, a promising asset currently in Phase 2b clinical trials for the treatment of Ulcerative Colitis and Crohn’s Disease, both forms of inflammatory bowel disease (IBD). … Read the full press release →

Posted in Business, Environment, Financial, France, Healthcare, Industrial, Investment, Management, News, Pharma & Biotech, Science

Tagged , , , , , , , , , , , ,